Insight

Reference

·

Primary source

·Preview

UCS (Universal Coverage Scheme) drug expenditure

~THB 60B

As ofFY2024·Sources2·Primary

National Health Security Office (NHSO) administers Universal Coverage for ~47M Thais; drug expenditure is material line in Thai pharma demand.

Compare plans →

Figure in context

National Health Security Office (NHSO) administers Universal Coverage for ~47M Thais; drug expenditure is material line in Thai pharma demand.

National Health Security Office (NHSO) administers Universal Coverage for ~47M Thais; drug expenditure is material line in Thai pharma demand.

Time scope

FY2024

Source basis

Primary source

Interpretation notes

What this tells you

National Health Security Office (NHSO) administers Universal Coverage for ~47M Thais; drug expenditure is material line in Thai pharma demand.

What not to do with it

Use the linked report for interpretation and keep basis differences explicit.

Related figures

Adjacent numbers that add context without drowning the value.

FY2024
~THB 250B

Thai pharmaceutical market size

PReMA, TPMA, FDA Thailand, IQVIA

FY2024
~70%

Pharma imports share

FDA Thailand, UN Comtrade HS 30

FY2024
~10-15%

GPO (Government Pharma Organisation) share

GPO annual report, NHSO

FY2024
~THB 40B combined

Listed pharma distributor revenue (Mega, DCC)

MEGA, DCC 56-1 FY2024

Report context

Thailand Pharmaceuticals Market Intelligence

Thailand's pharmaceuticals market reached approximately THB 280B in FY2024, split roughly 75% imported (originators, generics) and 25% domestic (GPO state, listed, private generics). Government Pharmaceutical Organisation is the state anchor for essential medicines, ARV, biosimilar manufacturing. Mega Lifesciences (SET: MEGA) is the largest Thai-listed pharma (~THB 16B revenue). Multinational originator subsidiaries (GSK, Pfizer, Novartis, Roche) lead originator, specialty supply. UCS, SSS, CSMBS multi-payer framework, NLEM reimbursement drive price-competition dynamics.

Open report →

Atlas actors in this figure's reports

Profiles covered in the report that cite this number.

Government Pharmaceutical Organisation (GPO)

Thai state pharmaceutical manufacturer; generics, HIV ARV, biosimilar, Strategic Stockpile; FY2024 revenue ~THB 16B.

GSK Thailand

UK-parent MNC originator Thai subsidiary; respiratory, vaccines, HIV, oncology; ~8% Thai market value share.

Mega Lifesciences

Largest Thai-listed pharma by revenue; emerging-market distribution franchise; FY2024 revenue ~THB 16B.

Novartis Thailand

Swiss-parent MNC specialty Thai subsidiary; oncology, cardiovascular, biosimilar; ~6% Thai market value share.

Pfizer Thailand

US-parent MNC originator Thai subsidiary; oncology, primary care, vaccines; ~7% Thai market value share.

Roche Thailand

Swiss-parent MNC specialty Thai subsidiary; oncology, biologics, diagnostics; ~5% Thai market value share.

UCS (Universal Coverage Scheme) drug expenditure · Insight